For what it is worth, Bell Potter issued an update of their MSB research on 29 Sept, attached becaus it may not be available to some shareholders.
The phase 2 RA results are now expected by 4QCY17. They also suggest discussions ongoing with MNK and potential additional parties which could be interested now that there are no exclusivity restraints any more. Bell suggests upfront payments for GvHD and Lower back pain deals of $80 mill and total deal value of $880.
Bell Potter of course has a vested interest as MSB is a client of theirs. I offer no opinion. please do your own research.
3 Things In Biotech You Should Learn Today: October 1, 2017, page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |